Capricor Therapeutics (CAPR) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01From inception, we have financed our operations through private and public sales of our equity securities, government grants and payments from distribution agreements and collaboration partners
2. 02covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates, or grant licenses on terms that may not be favorable to us
3. 03We have a history of net losses, and we expect losses to continue for the foreseeable future. In addition, a number of factors may cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance
4. 04The Company’s cell therapy technology (deramiocel) is in late-stage development but not yet an approved product, and its exosome technology is still in preclinical development
5. 05Our product candidates may, or in some cases, will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales
6. 06Business disruptions such as natural disasters, widespread infectious diseases, or pandemics or geopolitical conflicts could seriously harm our future revenues and financial condition and increase our costs and expenses
7. 07A breakdown, corruption or breach of our information technology systems or computer systems, or those used or hosted by our CROs, contractors, consultants or third-party vendors could subject us to liability or interrupt the operation of our business
8. 08If we achieve our near-term product development milestones, we may not be able to manage any subsequent growth

Risks Related to Clinical and Commercialization Activities

1. 09Our success depends upon the viability of our product candidates and we cannot be certain any of them will receive regulatory approval to be commercialized
2. 10We have limited experience in conducting late-stage clinical trials, which are complex and subject to strict regulatory oversight
3. 11As the results of earlier preclinical studies or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval
4. 12Our exosome technologies are based on a novel therapeutic approach which makes it difficult to predict the time and cost of development and the probability of subsequently obtaining regulatory approval, if at all
5. 13Negative developments in the field of exosomes could damage public perception of any product candidates that we develop, which could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates
6. 14demonstrated an inability to generate exosomes with predictable biologically active properties or to manufacture exosomes at suitable scale to treat more than a small number of patients. Our success will depend on our ability to demonstrate that our exosome technologies can overcome these challenges
7. 15We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to do so, the FDA may not permit us to proceed
8. 16Delays in the commencement, enrollment, and completion of clinical testing, as well as reduced government funding of certain clinical trials, could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates
9. 17Modifications to informed consent or other clinical trial requirements may affect enrollment or retention of patients, require modifications to trial documents and may cause delays to the trial
10. 18The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
11. 19The regulatory pathway for COVID-19 or other infectious disease vaccines is continually evolving and may result in unexpected or unforeseen challenges
12. 20We may not be successful in our efforts to identify or discover additional potential product candidates or additional indications for our existing product candidates
13. 21Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, our business would be harmed
14. 22Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
15. 23We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
16. 24The FDA has granted orphan drug status and an RMAT designation to deramiocel for the treatment of DMD, but we may be unable to maintain or receive the benefits associated with orphan drug status, including market exclusivity, or an RMAT designation
17. 25Even if we were to obtain approval for deramiocel for the treatment of DMD with the rare pediatric disease designation, the Rare Pediatric Disease Priority Review Voucher Program may no longer be in effect at the time of such approval
18. 26Providing product for use in third-party trials or for compassionate use poses risks to our product candidates
19. 27Our products face a risk of failure due to adverse immunological reactions
20. 28Our business faces significant government regulation, and there is no guarantee that our product candidates will receive regulatory approval
21. 29There are additional risks involved in conducting clinical trials internationally
22. 30Even if our product candidates receive regulatory approval, we may still face future development and FDA regulatory difficulties
23. 31If we or current or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and substantial penalties, which could affect our ability to develop, market and sell our products and may harm our reputation
24. 32Any drugs we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our future business prospects
25. 33federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program
26. 34Our risk mitigation measures cannot guarantee that we effectively manage all operational risks and that we are in compliance with all potentially applicable U.S. federal and state regulations and all potentially applicable foreign regulations and other requirements
27. 35Our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
28. 36Our ability to obtain reimbursement or funding for our programs from the federal government may be impacted by possible reductions in federal spending
29. 37Vaccines carry unique risks and uncertainties, which could have a negative impact on future results of operations

Risks Related to the Manufacturing of our Product Candidates

1. 38We have limited manufacturing capability and may not be able to maintain our manufacturing licenses
2. 39manufacturing expansion. We plan to build additional cleanrooms in this expanded space suitable for commercial manufacturing, subject to FDA approval
3. 40The process of manufacturing our products is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities
4. 41We will need to increase our manufacturing capacity in the future and we may encounter problems at our current manufacturing facilities
5. 42We are subject to a number of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates
6. 43We may need to rely exclusively on third parties to formulate and manufacture our product candidates and provide us with the devices and other products necessary to administer such a product
7. 44Disruptions in our supply chain or failure to adequately forecast product demand could result in significant delays or lost sales
8. 45Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties
9. 46The third parties we use in the manufacturing process for our product candidates may fail to comply with cGMP regulations

Risks Related to Our Intellectual Property

1. 47We may face uncertainty and difficulty in obtaining and enforcing our patents and other proprietary rights
2. 48litigation, if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management resources, and injunction against continued manufacture, use, or sale of certain products or processes
3. 49It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If we fail to protect or enforce our intellectual property rights adequately or secure rights to patents of others, the value of our intellectual property rights and product candidates would diminish
4. 50If any of our trade secrets, know-how or other proprietary information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer
5. 51We may incur substantial costs as a result of litigation or other adversarial proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology
6. 52We may be subject to claims that we or our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
7. 53We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business

Risks Related to Our Relationships with Third Parties

1. 54We will depend on our exclusive distributor, Nippon Shinyaku, for the commercial sale of our lead product deramiocel in DMD in the United States and Japan, if we receive regulatory approval in those territories
2. 55Our results of operations could be materially harmed if we or our distributor are unable to accurately forecast customer demand for our products and manage our inventory
3. 56We are dependent on our relationships with our licensors and collaborators and there is no guarantee that such relationships will be maintained or continued
4. 57In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to the proprietary technology
5. 58Commencing in 2009, we received several grants from the NIH and DoD to fund various projects. Some of these awards remain subject to annual and quarterly reporting requirements and require us to allocate expenses to the applicable project
6. 59If we enter into strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to terms unfavorable to us
7. 60We rely and will rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates
8. 61clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws and regulations
9. 62As we advance our programs through potential commercial launch, we have substantial fixed costs associated with third party contracts that will increase and will not be able to be terminated, even if our product candidates are not ultimately approved

Risks Related to Competitive Factors

1. 63Our products will likely face intense competition
2. 64If we do not establish strategic partnerships, we will have to undertake development and commercialization efforts on our own, which would be costly and delay our ability to commercialize any future products or product candidates
3. 65We have no experience selling, marketing, or distributing products and no current internal capability to do so
4. 66If any of our product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales, if any, will be limited
5. 67Our development of a potential vaccine for COVID-19 or other indications is at an early stage and is subject to significant risks
6. 68Even if our product candidates are approved, our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement

Risks Related to Product and Environmental Liability

1. 69Our products may expose us to potential product liability, and there is no guarantee that we will be able to obtain and maintain adequate insurance to cover these liabilities
2. 70Our business involves risk associated with handling hazardous and other dangerous materials
3. 71Our business depends on compliance with ever-changing environmental and human health and safety laws

Risks Related to Our Common Stock

1. 72We expect that our stock price will continue to fluctuate significantly
2. 73We have never paid dividends and we do not anticipate paying dividends in the future
3. 74We may issue shares of blank check preferred stock without stockholder approval in the future
4. 75Market and economic conditions may adversely affect our industry, business and ability to obtain financing
5. 76If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
6. 77The operational and other projections and forecasts that we may make from time to time are subject to inherent risks, many of which are beyond our control
7. 78Our certificate of incorporation and by-laws contain provisions that may discourage, delay or prevent a change in our management team that stockholders may consider favorable
8. 79These provisions could make it more difficult for our stockholders to affect our corporate policies or make changes in our Board of Directors and for a third-party to acquire us, even if doing so would benefit our stockholders
9. 80The Company’s ability to utilize Nile’s net operating loss and tax credit carryforwards in the future is subject to substantial limitations and may further be limited as a result of the merger with Capricor
10. 81The requirements of being a public company may strain our resources and divert management’s attention
11. 82Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price
12. 83You may experience future dilution as a result of future equity offerings
13. 84If our business plans are not successful, our stockholders may lose their entire investment in us
14. 85We may be at risk of securities class action litigation or litigation initiated by individual stockholders